Relationship of levetiracetam and obsessive-compulsive disorder: a case report

Çökmüş, Fikret Poyraz; Aşçıbaşı, Kadir; Öztekin, Siğnem; Demet, Mehmet Murat

doi:10.1080/24750573.2017.1342798

Cited by 4 publications

(9 citation statements)

References 11 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been similar reports, after having received 1000 to 1500 mg/d of levetiracetam in adults, most with preexisting cognitive impairments and intellectual disability. [6][7][8] In contrast to this, ours and the previous case 5 demonstrate levetiracetam-associated OC symptoms in typically developing individuals. We found that the adverse event appeared when levetiracetam was at 800 mg and improved completely when the drug was stopped with no alternative causes that could have caused the OC symptoms (Table 1).…”

contrasting

confidence: 90%

“…Like Fujikawa et al, 5 we found that the OC symptoms resolved completely after stopping of levetiracetam. There have been similar reports, after having received 1000 to 1500 mg/d of levetiracetam in adults, most with preexisting cognitive impairments and intellectual disability 6–8 . In contrast to this, ours and the previous case 5 demonstrate levetiracetam-associated OC symptoms in typically developing individuals.…”

supporting

confidence: 82%

“…On the contrary, some authors have reported efficacy of levetiracetam for OC-related phenomena, specifically body dysmorphic disorder 13,14 . This somewhat contrasting evidence may point toward modulatory effects on the glutamatergic system rather than a simple and straightforward agonistic/antagonistic action as suggested by earlier authors 5,8 …”

mentioning

confidence: 94%

See 2 more Smart Citations

Levetiracetam-Associated Obsessive-Compulsive Symptoms in a Preschooler

Yumnam

Bhagwat

Saini

et al. 2021

J Clin Psychopharmacol

View full text Add to dashboard Cite

contrasting

confidence: 90%

supporting

confidence: 82%

See 1 more Smart Citation

Levetiracetam-Associated Obsessive-Compulsive Symptoms in a Preschooler

Yumnam

Bhagwat

Saini

et al. 2021

J Clin Psychopharmacol

View full text Add to dashboard Cite

“…However, a possible role for SV2A itself driving compulsions was previously demonstrated in a clinical setting. Epilepsy patients were shown to develop compulsive behaviours upon administration of the SV2A-targeting antiepileptic drug levetiracetam [42,44,45,74].…”

Section: Discussionmentioning

confidence: 99%

“…Also from a clinical point of view, there is emerging-mainly genetic-evidence for "synaptopathies" as a hallmark in the development of OCD [32][33][34][35][36] and other neuropsychiatric diseases [37][38][39][40][41]. Moreover, the SV2A targeting antiepileptic drug levetiracetam [42] was associated earlier with adverse psychiatric reactions, including the occurrence of obsessive-compulsive behaviours [43][44][45]. Differently, another case report demonstrated the ability of levetiracetam to treat a refractory OCD patient [46].…”

Section: Introductionmentioning

confidence: 99%

Sapap3 deletion causes dynamic synaptic density abnormalities: a longitudinal [11C]UCB-J PET study in a model of obsessive–compulsive disorder-like behaviour

et al. 2020

View full text Add to dashboard Cite

Background Currently, the evidence on synaptic abnormalities in neuropsychiatric disorders—including obsessive–compulsive disorder (OCD)—is emerging. The newly established positron emission tomography (PET) ligand ((R)-1-((3-((11)C-methyl-(11)C)pyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one) ([11C]UCB-J) provides the opportunity to visualize synaptic density changes in vivo, by targeting the synaptic vesicle protein 2A (SV2A). Here, we aim to evaluate such alterations in the brain of the SAP90/PSD-95-associated protein 3 (Sapap3) knockout (ko) mouse model, showing an abnormal corticostriatal neurotransmission resulting in OCD-like behaviour. Methods Longitudinal [11C]UCB-J µPET/CT scans were acquired in Sapap3 ko and wildtype (wt) control mice (n = 9/group) to study SV2A availability. Based on the Logan reference method, we calculated the volume of distribution (VT(IDIF)) for [11C]UCB-J. Both cross-sectional (wt vs. ko) and longitudinal (3 vs. 9 months) volume-of-interest-based statistical analysis and voxel-based statistical parametric mapping were performed. Both [11C]UCB-J ex vivo autoradiography and [3H]UCB-J in vitro autoradiography were used for the validation of the µPET data. Results At the age of 3 months, Sapap3 ko mice are already characterized by a significantly lower SV2A availability compared to wt littermates (i.a. cortex − 12.69%, p < 0.01; striatum − 14.12%, p < 0.001, thalamus − 13.11%, p < 0.001, and hippocampus − 12.99%, p < 0.001). Healthy ageing in control mice was associated with a diffuse and significant (p < 0.001) decline throughout the brain, whereas in Sapap3 ko mice this decline was more confined to the corticostriatal level. A strong linear relationship (p < 0.0001) was established between the outcome parameters of [11C]UCB-J µPET and [11C]UCB-J ex vivo autoradiography, while such relationship was absent for [3H]UCB-J in vitro autoradiography. Conclusions [11C]UCB-J PET is a potential marker for synaptic density deficits in the Sapap3 ko mouse model for OCD, parallel to disease progression. Our data suggest that [11C]UCB-J ex vivo autoradiography is a suitable proxy for [11C]UCB-J PET data in mice.

show abstract

Levetiracetam

2018

Reactions Weekly

View full text Add to dashboard Cite

Relationship of levetiracetam and obsessive-compulsive disorder: a case report

Cited by 4 publications

References 11 publications

Levetiracetam-Associated Obsessive-Compulsive Symptoms in a Preschooler

Levetiracetam-Associated Obsessive-Compulsive Symptoms in a Preschooler

Sapap3 deletion causes dynamic synaptic density abnormalities: a longitudinal [11C]UCB-J PET study in a model of obsessive–compulsive disorder-like behaviour

Levetiracetam

Contact Info

Product

Resources

About